Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ARQL ArQule (ARQL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About ArQule Stock (NASDAQ:ARQL) 30 days 90 days 365 days Advanced Chart Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get ArQule alerts:Sign Up Key Stats Today's Range$20.00▼$20.0050-Day Range$20.00▼$20.0052-Week Range$3.15▼$20.45VolumeN/AAverage Volume5.27 million shsMarket Capitalization$2.42 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.Read More… JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Receive ARQL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArQule and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQL Stock News HeadlinesMerck Sharp & Dohme Corp.'s Net WorthMarch 22, 2024 | benzinga.comASCO Live Blog: SaturdayJune 30, 2023 | thestreet.comLet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! November 21, 2024 | DTI (Ad)2023 Fibroblast Growth Factor Receptor 2 Inhibitor Market Share and Growth Rate Forecast for 2030May 5, 2023 | marketwatch.comWelcome to My Portfolio - Link your brokers or add lotsApril 3, 2023 | finance.yahoo.com40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight - GlobeNewswireSeptember 21, 2022 | globenewswire.comForm SC 13E3 Stealth BioTherapeutics Filed by: Stealth BioTherapeutics Corp - StreetInsider.comAugust 21, 2022 | streetinsider.comMerus Stock: Precision Oncology Pioneer Executes In The Clinic (NASDAQ:MRUS) - Seeking AlphaJune 30, 2022 | seekingalpha.comSee More Headlines ARQL Stock Analysis - Frequently Asked Questions How were ArQule's earnings last quarter? ArQule, Inc. (NASDAQ:ARQL) posted its earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The biotechnology company earned $0.21 million during the quarter, compared to the consensus estimate of $1.20 million. ArQule had a negative trailing twelve-month return on equity of 33.10% and a negative net margin of 805.61%. What other stocks do shareholders of ArQule own? Based on aggregate information from My MarketBeat watchlists, some other companies that ArQule investors own include Amarin (AMRN), Verastem (VSTM), Celldex Therapeutics (CLDX), Corbus Pharmaceuticals (CRBP), Advanced Micro Devices (AMD), Novavax (NVAX) and Axsome Therapeutics (AXSM). Company Calendar Last Earnings10/30/2019Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ARQL CUSIP04269E10 CIK1019695 Webwww.arqule.com Phone781-994-0300FaxN/AEmployees36Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,480,000.00 Net Margins-805.61% Pretax MarginN/A Return on Equity-33.10% Return on Assets-26.87% Debt Debt-to-Equity Ratio0.08 Current Ratio8.27 Quick Ratio8.27 Sales & Book Value Annual Sales$25.76 million Price / Sales93.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book27.78Miscellaneous Outstanding Shares120,873,000Free FloatN/AMarket Cap$2.42 billion OptionableOptionable Beta2.49 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:ARQL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArQule, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArQule With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.